Most-cited articles · 2020
The 50 most-cited articles in Value in Health, 2020
Ranked by OpenAlex citation count on 29 October 2026, out of 867 eligible articles Value in Health published in 2020. Ranks are frozen; this page will not change. Number one, with 205 citations: Value of Information Analysis for Research Decisions—An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force.
- Cohort
- 867 articles
- Listed
- Top 50 (5.8%)
- Open access
- 50 of 50
- Snapshot
- 2026-10-29
The most-cited Value in Health articles of 2020 cluster around a few dominant themes: value of information and research prioritization methods, systematic reviews of care delivery and patient flow, and patient engagement and real-world evidence. The top paper, "Value of Information Analysis for Research Decisions—An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force" by Fenwick, Steuten, Knies and colleagues, has 205 citations. Other highly cited works address lean healthcare, patient engagement in research, and partitioned survival models in oncology.
Readers can use this list to see which topics attracted the most citation attention in the journal that year. The entries span methodological guidance, systematic reviews, and policy analyses, and each is linked to its authors and citation count.
Introduction written from the titles and abstracts on this list. Every figure below is the source.
Ask about these papers
Grounded in this list only, with sources.
- 1top 0.2%
Value of Information Analysis for Research Decisions—An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force
Elisabeth A. L. Fenwick, Lotte Steuten, Saskia Knies, Salah Ghabri, Anirban Basu and 5 more
205 citationsOpen accessdoi:10.1016/j.jval.2020.01.001OpenAlex
- 2top 0.3%
Effects of Lean Healthcare on Patient Flow: A Systematic Review
Diego Tlapa, Carlos Zepeda-Lugo, Guilherme Luz Tortorella, Yolanda Angelica Baez-Lopez, Jorge Limón-Romero and 2 more
179 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2019.11.002OpenAlex
Show abstractHide abstract
OBJECTIVES: To assess the effects of lean healthcare (LH) on patient flow in ambulatory care and determine whether waiting time and length of stay (LOS) decrease after LH interventions. METHODS: A systematic review was performed with close adherence to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). We searched for studies of healthcare organizations applying LH interventions within ambulatory care published between 2002 and 2018. Six databases and grey literature sources were used. Two reviewers independently screened and assessed each study. When consensus was difficult to reach, a third reviewer intervened. Finally, a summary of findings was generated. RESULTS: Out of 5627 studies, 40 were included. Regarding LOS for all patients, 19 out of 22 studies reported a decrease. LOS for discharged patients decreased in 11 out of 13 studies, whereas LOS for admitted patients was reduced in 6 out of 7 studies. Waiting time for patients before seeing a healthcare professional decreased in 24 out of 26 studies. Waiting time to treatment and waiting time for…
- 3top 0.4%
Defining Patient Engagement in Research: Results of a Systematic Review and Analysis: Report of the ISPOR Patient-Centered Special Interest Group
Rachel L. Harrington, Maya Hanna, Elisabeth M. Oehrlein, Rob Camp, Russell Wheeler and 8 more
172 citationsOpen accessdoi:10.1016/j.jval.2020.01.019OpenAlex
- 4top 0.5%
Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now?
Beth S. Woods, Eleftherios Sideris, Stephen Palmer, Nicholas R. Latimer, Marta O. Soares
152 citationsOpen accessdoi:10.1016/j.jval.2020.08.2094OpenAlex
- 5top 0.6%
Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force
Claire Rothery, Mark Strong, Hendrik Koffijberg, Anirban Basu, Salah Ghabri and 5 more
130 citationsOpen accessdoi:10.1016/j.jval.2020.01.004OpenAlex
- 6top 0.7%
Advances in Value-Based Healthcare by the Application of Time-Driven Activity-Based Costing for Inpatient Management: A Systematic Review
Ana Paula Beck da Silva Etges, Karen Brasil Ruschel, Carísi Anne Polanczyk, Richard D. Urman
129 citationsOpen accessdoi:10.1016/j.jval.2020.02.004OpenAlex
- 7top 0.9%
Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing—Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative
Lucinda Strycker Orsini, Marc L. Berger, William H. Crown, Gregory W. Daniel, Hans‐Georg Eichler and 11 more
126 citationsOpen accessdoi:10.1016/j.jval.2020.04.002OpenAlex
- 8top 1%
Distributional Cost-Effectiveness Analysis Comes of Age
Richard Cookson, Susan C. Griffin, Ole Frithjof Norheim, Anthony J. Culyer, Kalipso Chalkidou
121 citationsOpen access (CC-BY)doi:10.1016/j.jval.2020.10.001OpenAlex
Show abstractHide abstract
Distributional cost-effectiveness analysis (DCEA) provides information about the equity impacts of health technologies and programs and the trade-offs that sometimes arise between equity and efficiency. This field has now come of age with a growing applied literature,1 new training resources,2 and a formal professional network: a special interest group on equity-informative economic evaluation within the International Health Economics Association.3
- 9top 1.1%
Use of Real-World Evidence to Support FDA Approval of Oncology Drugs
Bruce A. Feinberg, Ajeet Gajra, Marjorie E. Zettler, Todd D. Phillips, Eli G. Phillips and 1 more
121 citationsOpen accessdoi:10.1016/j.jval.2020.06.006OpenAlex
- 10top 1.2%
Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary
Fanni Rencz, Valentin Brodszky, László Gulàcsi, Dominik Golicki, G Ruzsa and 3 more
115 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2020.03.019OpenAlex
Show abstractHide abstract
OBJECTIVES: The wording of the Hungarian EQ-5D-3L and EQ-5D-5L descriptive systems differ a great deal. This study aimed to (1) develop EQ-5D-3L and EQ-5D-5L value sets for Hungary from a common sample, and (2) compare how level wording affected valuations. METHODS: In 2018 to 2019, 1000 respondents, representative of the Hungarian general population, completed composite time trade-off tasks. Pooled heteroscedastic Tobit models were used to estimate value sets. Value set characteristics, single-level transition utilities from adjacent corner health states, and mean transition utilities for all possible health states were compared between the EQ-5D-3L and EQ-5D-5L. RESULTS: Health utilities ranged from -0.865 to 1 for the EQ-5D-3L and -0.848 to 1 for the EQ-5D-5L. The relative importance of the 5 EQ-5D-5L dimensions was as follows: mobility, pain/discomfort, self-care, anxiety/depression, and usual activities. A similar preference ranking was observed for the EQ-5D-3L with self-care being more important than pain/discomfort. The EQ-5D-5L demonstrated lower ceiling effects (range of…
- 11top 1.3%
Managed Entry Agreements: Policy Analysis From the European Perspective
Monique Dabbous, Lylia Chachoua, Aleksandra Caban, Mondher Toumi
113 citationsOpen accessdoi:10.1016/j.jval.2019.12.008OpenAlex
- 12top 1.4%
Disparities in Access to Opioid Treatment Programs and Office-Based Buprenorphine Treatment Across the Rural-Urban and Area Deprivation Continua: A US Nationwide Small Area Analysis
Solmaz Amiri, Michael G. McDonell, Justin T. Denney, Dedra Buchwald, Ofer Amram
111 citationsOpen accessdoi:10.1016/j.jval.2020.08.2098OpenAlex
- 13top 1.5%
Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the Personalized Precision Medicine Special Interest Group
Eric C. Faulkner, Anke‐Peggy Holtorf, Surrey M. Walton, Christine Y. Liu, Hwee Lin and 11 more
111 citationsOpen accessdoi:10.1016/j.jval.2019.11.010OpenAlex
- 14top 1.7%
Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis
Adrienne Y L Chan, Vivien Kin Yi Chan, Sten Olsson, Min Fan, Mark Jit and 13 more
103 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2020.06.020OpenAlex
Show abstractHide abstract
OBJECTIVES: Three hundred million people living with rare diseases worldwide are disproportionately deprived of in-time diagnosis and treatment compared with other patients. This review provides an overview of global policies that optimize development, licensing, pricing, and reimbursement of orphan drugs. METHODS: Pharmaceutical legislation and policies related to access and regulation of orphan drugs were examined from 194 World Health Organization member countries and 6 areas. Orphan drug policies (ODPs) were identified through internet search, emails to national pharmacovigilance centers, and systematic academic literature search. Texts from selected publications were extracted for content analysis. RESULTS: One hundred seventy-two drug regulation documents and 77 academic publications from 162 countries/areas were included. Ninety-two of 200 countries/areas (46.0%) had documentation on ODPs. Thirty-four subthemes from content analysis were categorized into 6 policy themes, namely, orphan drug designation, marketing authorization, safety and efficacy requirements, price…
- 15top 1.8%
Examining Equity Effects of Health Interventions in Cost-Effectiveness Analysis: A Systematic Review
Anton L.V. Avanceña, Lisa A. Prosser
84 citationsOpen access (CC-BY)doi:10.1016/j.jval.2020.10.010OpenAlex
Show abstractHide abstract
OBJECTIVE: This systematic review aims to catalogue and describe published applications of equity-informative cost-effectiveness analysis (CEAs). METHODS: Following PRISMA guidelines, we searched Medline for English-language, peer-reviewed CEAs published on or before August 2019. We included CEAs that evaluated 2 or more alternatives; explicitly mentioned equity as a consideration or decision-making principle; and applied an equity-informative CEA method to analyze or examine at least 1 equity criterion in an applied CEA. We extracted data on selected characteristics and analyzed reporting quality using the CHEERS checklist. RESULTS: Fifty-four articles identified through a search and bibliography reviews met the inclusion criteria. All articles were published on or after 2010, with 80% published after 2015. Most studies evaluated primary prevention interventions in disease areas such as cancer, infectious diseases, and cardiovascular disease. Equity impact analysis alone was the most common equity-informative CEA (56%), followed by equity impact analysis with financial protection…
- 16top 1.9%
Content of Health Economics Analysis Plans (HEAPs) for Trial-Based Economic Evaluations: Expert Delphi Consensus Survey
Joanna C. Thorn, Charlotte F. Davies, SARA T. BROOKES, Sian Noble, Melina Dritsaki and 9 more
70 citationsOpen access (CC-BY)doi:10.1016/j.jval.2020.10.002OpenAlex
Show abstractHide abstract
OBJECTIVES: Health economics analysis plans (HEAPs) currently lack consistency, with uncertainty surrounding appropriate content. We aimed to develop a list of essential items that should be included in HEAPs for economic evaluations conducted alongside randomized trials. METHODS: A list of potential items for inclusion was developed by examining existing HEAPs. An electronic Delphi survey was conducted among professional health economists. Respondents were asked to rate potential items from 1 (least important) to 9 (most important), suggest additional items, and comment on proposed items (round 1). A second survey (round 2) was emailed to participants, including the participant's own scores from round 1 along with summary results from the whole panel; participants were asked to rerate each item. Consensus criteria for inclusion in the final list were predefined as >70% of participants rating an item 7-9 and <15% rating it 1-3 after round 2. A final item selection meeting was held to scrutinize the results and adjudicate on items lacking consensus. RESULTS: 62 participants completed…
- 17top 2%
A Review of the Psychometric Performance of Selected Child and Adolescent Preference-Based Measures Used to Produce Utilities for Child and Adolescent Health
Donna Rowen, Anju Devianee Keetharuth, Edith N Poku, Ruth Wong, Becky Pennington and 1 more
67 citationsOpen accessdoi:10.1016/j.jval.2020.09.012OpenAlex
- 18top 2.1%
Computing the Expected Value of Sample Information Efficiently: Practical Guidance and Recommendations for Four Model-Based Methods
Natalia Kunst, Ed Wilson, David Glynn, Fernando Alarid‐Escudero, Gianluca Baio and 9 more
66 citationsOpen accessdoi:10.1016/j.jval.2020.02.010OpenAlex
- 19top 2.2%
Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations
Rick A. Vreman, Aukje Kaija Mantel-Teeuwisse, Anke Marijn Hövels, Hubert G. M. Leufkens, Wim Goettsch
64 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2019.07.017OpenAlex
Show abstractHide abstract
BACKGROUND: Health technology assessment (HTA) plays an important role in reimbursement decision-making in many countries, but recommendations vary widely throughout jurisdictions, even for the same drug. This variation may be due to differences in the weighing of evidence or differences in the processes or procedures, which are known as HTA practices. OBJECTIVE: To provide insight into the effects of differences in practices on interpretation of intercountry differences in HTA recommendations for conditionally approved drugs. METHODS: HTA recommendations for conditionally approved drugs (N = 27) up until June 2017 from England/Wales, France, Germany, the Netherlands, and Scotland were included. Recommendations and practice characteristics were extracted from these five jurisdictions and this data was validated. The effect of nonsubmissions, resubmissions, and reassessments; cost-effectiveness assessments; and price negotiations on changes in the percentage of negative recommendations and the interpretation of intercountry differences in HTA outcomes were analyzed using Fisher exact…
- 20top 2.4%
A Systematic Review of Economic Evaluations Reporting the Cost-Effectiveness of Spinal Cord Stimulation
Siwaporn Niyomsri, Rui V. Duarte, Sam S. Eldabe, Gregory J. Fiore, Brian Harris Kopell and 2 more
63 citationsOpen access (CC-BY)doi:10.1016/j.jval.2020.02.005OpenAlex
Show abstractHide abstract
OBJECTIVES: Spinal cord stimulation (SCS) is a recognized treatment for chronic pain. This systematic review aims to assess economic evaluations of SCS for the management of all chronic pain conditions, summarize key findings, and assess the quality of studies to inform healthcare resource allocation decisions and future research. METHODS: Economic evaluations were identified by searching general medical and economic databases complemented with screening of reference lists of identified studies. No restrictions on language or treatment comparators were applied. Relevant data were extracted. The quality of included studies was assessed using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist. RESULTS: Fourteen studies met the inclusion criteria and were judged to be of acceptable quality. Economic evaluations assessed SCS for the management of refractory angina pectoris, failed back surgery syndrome (FBSS), complex regional pain syndrome (CRPS), diabetic peripheral neuropathy (DPN), and peripheral arterial disease. Model-based studies typically applied…
- 21top 2.5%
Disease Burden Attributable to the First Wave of COVID-19 in China and the Effect of Timing on the Cost-Effectiveness of Movement Restriction Policies
Jidi Zhao, Huajie Jin, Xun Li, Jianguo Jia, Chao Zhang and 10 more
60 citationsOpen accessdoi:10.1016/j.jval.2020.12.009OpenAlex
- 22top 2.6%
Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation Modeling
Deborah Anne Marshall, Luiza Raquel Grazziotin, Dean A. Regier, Sarah Wordsworth, James Buchanan and 2 more
59 citationsOpen accessdoi:10.1016/j.jval.2020.01.016OpenAlex
- 23top 2.7%
Announcing the New Definition of Health Technology Assessment
Brian P. O’Rourke, Wija Oortwijn, Tara Schuller
58 citationsOpen accessdoi:10.1016/j.jval.2020.05.001OpenAlex
- 24top 2.8%
Inclusion of Carer Health-Related Quality of Life in National Institute for Health and Care Excellence Appraisals
Becky M. Pennington
57 citationsOpen accessdoi:10.1016/j.jval.2020.05.017OpenAlex
- 25top 2.9%
Estimating a Preference-Based Index for Mental Health From the Recovering Quality of Life Measure: Valuation of Recovering Quality of Life Utility Index
Anju Devianee Keetharuth, Donna Rowen, Jakob Bue Bjørner, John Edward Brazier
56 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2020.10.012OpenAlex
Show abstractHide abstract
BACKGROUND: There are increasing concerns about the appropriateness of generic preference-based measures to capture health benefits in the area of mental health. OBJECTIVES: The aim of this study is to estimate preference weights for a new measure, Recovering Quality of Life (ReQoL-10), to better capture the benefits of mental healthcare. METHODS: Psychometric analyses of a larger sample of mental health service users (n = 4266) using confirmatory factor analyses and item response theory were used to derive a health state classification system and inform the selection of health states for utility assessment. A valuation survey with members of the UK public representative in terms of age, sex, and region was conducted using face-to-face interviewer administered time-trade-off with props. A series of regression models were fitted to the data and the best performing model selected for the scoring algorithm. RESULTS: The ReQoL-Utility Index (UI) classification system comprises 6 mental health items and 1 physical health item. Sixty-four health states were valued by 305 participants. The…
- 26top 3%
The EQ-5D-5L Value Set for England: Findings of a Quality Assurance Program
Mónica Hernández Alava, Stephen E. Pudney, Allan Wailoo
56 citationsOpen accessdoi:10.1016/j.jval.2019.10.017OpenAlex
- 27top 3.2%
Willingness to Accept Trade-Offs Among COVID-19 Cases, Social-Distancing Restrictions, and Economic Impact: A Nationwide US Study
Shelby D. Reed, Juan Marcos González, F. Reed Johnson
54 citationsOpen accessdoi:10.1016/j.jval.2020.07.003OpenAlex
- 28top 3.3%
Estimation of an Instrument-Defined Minimally Important Difference in EQ-5D-5L Index Scores Based on Scoring Algorithms Derived Using the EQ-VT Version 2 Valuation Protocols
Edward Henry, Luke E. Barry, Anna P. Hobbins, Nathan S. McClure, Ciarán O’Neill
54 citationsOpen access (CC-BY)doi:10.1016/j.jval.2020.03.003OpenAlex
Show abstractHide abstract
OBJECTIVES: To estimate and compare the minimally important difference (MID) in index score of country-specific EQ-5D-5L scoring algorithms developed using EuroQol Valuation Technology protocol version 2, including algorithms from Germany, Indonesia, Ireland, Malaysia, Poland, Portugal, Taiwan, and the United States. METHODS: A simulation-based approach contingent on all single-level transitions defined by the EQ-5D-5L descriptive system was used to estimate the MID for each algorithm. RESULTS: The resulting mean (and standard deviation) instrument-defined MID estimates were Germany, 0.083 (0.022); Indonesia, 0.093 (0.012); Ireland, 0.098 (0.023); Malaysia, 0.072 (0.010); Poland, 0.080 (0.030); Portugal, 0.080 (0.018); Taiwan, 0.101 (0.010); and the United States, 0.078 (0.014). CONCLUSIONS: These population preference-based MID estimates and accompanying evidence of how such values vary as a function of baseline index score can be used to aid interpretation of index score change. The marked consistency in the relationship between the calculated MID estimate and the range of the…
- 29top 3.4%
A Review of the Methods Used to Generate Utility Values in NICE Technology Assessments for Children and Adolescents
Harry R. Hill, Donna Rowen, Becky Pennington, Ruth Wong, Allan Wailoo
53 citationsOpen accessdoi:10.1016/j.jval.2020.02.011OpenAlex
- 30top 3.5%
Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions—Report of the ISPOR Stated Preference Research Special Interest Group
Kevin Marsh, Janine Astrid van Til, Elizabeth Molsen-David, Christin Juhnke, Natalia Hawken and 13 more
52 citationsOpen access (PUBLIC-DOMAIN)doi:10.1016/j.jval.2019.11.009OpenAlex
Show abstractHide abstract
OBJECTIVE: This study examines European decision makers' consideration and use of quantitative preference data. METHODS: The study reviewed quantitative preference data usage in 31 European countries to support marketing authorization, reimbursement, or pricing decisions. Use was defined as: agency guidance on preference data use, sponsor submission of preference data, or decision-maker collection of preference data. The data could be collected from any stakeholder using any method that generated quantitative estimates of preferences. Data were collected through: (1) documentary evidence identified through a literature and regulatory websites review, and via key opinion leader outreach; and (2) a survey of staff working for agencies that support or make healthcare technology decisions. RESULTS: Preference data utilization was identified in 22 countries and at a European level. The most prevalent use (19 countries) was citizen preferences, collected using time-trade off or standard gamble methods to inform health state utility estimation. Preference data was also used to: (1) value…
- 31top 3.6%
Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision Making
T.A. Tai, Nicholas R. Latimer, Ágnes Benedict, Zsófia Kiss, Andreas Nikolaou
51 citationsOpen accessdoi:10.1016/j.jval.2020.10.016OpenAlex
- 32top 3.7%
Value of a QALY for France: A New Approach to Propose Acceptable Reference Values
B. Téhard, B. Detournay, Isabelle Borget, Stéphane Roze, Gérard de Pouvourville
49 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2020.04.001OpenAlex
Show abstractHide abstract
OBJECTIVE: France has included health economic assessment (HEA) as an official criterion for innovative drug pricing since 2013. Until now, no cost-effectiveness threshold (CET) has been officially proposed to qualify incremental cost-effectiveness ratios (ICERs). Although the French health authorities have publicly expressed the need for such reference values, previous initiatives to determine these have failed. The study aims to propose a locally adapted method for estimating a preference-based value for a quality-adjusted life-year (QALY) based on a rational approach to public policy choices in France. METHODS: We used the official French value of statistical life (VSL) of €3 million (USD 3.25 million), proposed in 2013 by the French General Commission on Strategy and Prediction. We first estimated the value of life-year (VoLY) by age category according to life expectancy and official discounts recommended for HEA in France. We then estimated a value of statistical QALY (VSQ) by weighting VoLYs with demographic data and French EQ-5D-3L tariffs. RESULTS: The estimated average…
- 33top 3.9%
Nonproportional Hazards in Network Meta-Analysis: Efficient Strategies for Model Building and Analysis
Anna S. Wiksten, Neil Hawkins, Hans‐Peter Piepho, Sandro Gsteiger
48 citationsOpen accessdoi:10.1016/j.jval.2020.03.010OpenAlex
- 34top 4%
Replication of Randomized, Controlled Trials Using Real-World Data: What Could Go Wrong?
David Thompson
47 citationsOpen accessdoi:10.1016/j.jval.2020.09.015OpenAlex
- 35top 4.1%
Improving Academic Biobank Value and Sustainability Through an Outputs Focus
Amanda Rush, Daniel Robin Catchpoole, Rod Ling, Andrew Searles, Peter Hamilton Watson and 1 more
47 citationsOpen accessdoi:10.1016/j.jval.2020.05.010OpenAlex
- 36top 4.2%
Economic Benefits of Immunization for 10 Pathogens in 94 Low- and Middle-Income Countries From 2011 to 2030 Using Cost-of-Illness and Value-of-Statistical-Life Approaches
Elizabeth A. Watts, So Yoon Sim, Dagna O. Constenla, Salin Sriudomporn, Logan Brenzel and 1 more
45 citationsOpen accessdoi:10.1016/j.jval.2020.07.009OpenAlex
- 37top 4.3%
A Systematic Review of the Feasibility and Psychometric Properties of the ICEpop CAPability Measure for Adults and Its Use So Far in Economic Evaluation
Nafsika Afentou, Philip Kinghorn
45 citationsOpen accessdoi:10.1016/j.jval.2019.12.010OpenAlex
- 38top 4.4%
Patient–Provider Discussion About Cancer Treatment Costs and Out-of-Pocket Spending: Implications for Shared Decision Making in Cancer Care
Young‐Rock Hong, Ramzi George Salloum, Sandhya Yadav, Grace L. Smith, Arch G. Mainous
44 citationsOpen accessdoi:10.1016/j.jval.2020.08.002OpenAlex
- 39top 4.5%
Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge
Lei Si, Michael S. Willis, Christian Asseburg, Andreas Nilsson, Michelle Tew and 21 more
44 citationsOpen accessdoi:10.1016/j.jval.2020.04.1832OpenAlex
- 40top 4.7%
Cost-Effectiveness of 4CMenB Infant Vaccination in England: A Comprehensive Valuation Considering the Broad Impact of Serogroup B Invasive Meningococcal Disease
Ekkehard C. Beck, Johan Klint, Mohamed El Moctar Neine, Stéphanie Garcia, Kinga Meszaros
43 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2020.09.004OpenAlex
Show abstractHide abstract
OBJECTIVES: This cost-effectiveness analysis (CEA) of 4CMenB infant vaccination in England comprehensively considers the broad burden of serogroup B invasive meningococcal disease (MenB IMD), which has not been considered, or was only partially considered in previous CEAs. METHODS: A review of previous MenB vaccination CEAs was conducted to identify aspects considered in the evaluation of costs and health outcomes of the disease burden of MenB IMD. To inform the model structure and comprehensive analysis, the aspects were grouped into 5 categories. A stepwise analysis was conducted to analyze the impact of each category, and the more comprehensive consideration of disease burden, on the incremental cost-effectiveness ratio (ICER). RESULTS: MenB IMD incidence decreased by 46.0% in infants and children 0-4 years old within 5 years after introduction of the program. Stepwise inclusion of the 5 disease burden categories to a conventional narrow CEA setting reduced the ICER from £360 595 to £18 645-that is, considering the impact of all 5 categories, 4CMenB infant vaccination is…
- 41top 4.8%
Validity and Responsiveness of Preference-Based Quality-of-Life Measures in Informal Carers: A Comparison of 5 Measures Across 4 Conditions
Carol McLoughlin, Ilias Goranitis, Hareth Al‐Janabi
43 citationsOpen access (CC-BY)doi:10.1016/j.jval.2020.01.015OpenAlex
Show abstractHide abstract
OBJECTIVES: Carer quality-of-life (QoL) effects are recommended for inclusion in economic evaluations, but little is known about the relative performance of different types of QoL measures with carers. This study evaluated the validity and responsiveness of 3 care-related QoL measures (the Carer Experience Scale [CES], CarerQoL-7D, and ASCOT-Carer), 1 health-related QoL measure (the EQ-5D-5L), and 1 generic QoL measure (the ICECAP-A). METHODS: Validity and responsiveness were assessed in a UK sample of informal carers of adults with dementia, stroke, mental illness, or rheumatoid arthritis. A questionnaire containing the 5 QoL measures was posted to carers identified through the Family Resources Survey (N = 1004). Hypotheses regarding the anticipated associations between constructs related to the QoL of carers were tested to investigate construct validity and responsiveness. RESULTS: Each measure exhibited some level of construct validity. In general, larger effect sizes and stronger associations were detected for the ASCOT-Carer and ICECAP-A measures in the pooled sample and across…
- 42top 4.9%
Peruvian Valuation of the EQ-5D-5L: A Direct Comparison of Time Trade-Off and Discrete Choice Experiments
Federico Augustovski, María Belizán, Luz Gibbons, Nora Reyes Puma, Elly A. Stolk and 2 more
42 citationsOpen accessdoi:10.1016/j.jval.2020.05.004OpenAlex
- 43top 5%
A Systematic Review and Meta-Analysis of Change in Health-Related Quality of Life for Interactive Telehealth Interventions for Patients With Asthma
Centaine L. Snoswell, Miia Rahja, AISLINN FELICITY LALOR
40 citationsOpen accessdoi:10.1016/j.jval.2020.09.006OpenAlex
- 44top 5.1%
Costing the COVID-19 Pandemic: An Exploratory Economic Evaluation of Hypothetical Suppression Policy in the United Kingdom
Darshan Zala, Iris Mosweu, Simone Critchlow, Renée Romeo, Paul McCrone
40 citationsOpen accessdoi:10.1016/j.jval.2020.07.001OpenAlex
- 45top 5.2%
The Preferred Qualities of Human Immunodeficiency Virus Testing and Self-Testing Among Men Who Have Sex With Men: A Discrete Choice Experiment
Jason J. Ong, Richard De Abreu Lourenço, Deborah J. Street, Kirsty S. Smith, Muhammad Shahid Jamil and 12 more
40 citationsOpen accessdoi:10.1016/j.jval.2020.04.1826OpenAlex
- 46top 5.4%
Patient-Reported Morbidity Instruments: A Systematic Review
Arvind Oemrawsingh, Nishwant S. Swami, José M Valderas, Jan Antonius Hazelzet, Andrea L. Pusic and 2 more
40 citationsOpen accessdoi:10.1016/j.jval.2020.02.006OpenAlex
- 47top 5.5%
Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing–Based Tests: Challenges, Opportunities, and Potential Solutions
Patricia A. Deverka, Michael P. Douglas, Kathryn A. Phillips
40 citationsOpen accessdoi:10.1016/j.jval.2020.02.001OpenAlex
- 48top 5.6%
Adjusting for Treatment Switching in Oncology Trials: A Systematic Review and Recommendations for Reporting
Thomas Sullivan, Nicholas R. Latimer, Jodi Gray, Michael Joseph Sorich, Amy B. Salter and 1 more
40 citationsOpen accessdoi:10.1016/j.jval.2019.10.015OpenAlex
- 49top 5.7%
An Economic Evaluation of the Cost-Effectiveness of Opt-Out Hepatitis B and Hepatitis C Testing in an Emergency Department Setting in the United Kingdom
Jack Williams, Peter T. Vickerman, Sam T Douthwaite, Gaia Nebbia, Laura J Hunter and 3 more
39 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.jval.2020.03.014OpenAlex
Show abstractHide abstract
OBJECTIVES: The prevalence of hepatitis is high in emergency department (ED) attendees in the United Kingdom, with a prevalence of up to 2% for hepatitis B (HBV) HBsAg, and 2.9% for hepatitis C (HCV) RNA. The aim of this paper is to perform an economic evaluation of opt-out ED-based HCV and HBV testing. METHODS: A Markov model was developed to analyze the cost-effectiveness of opt-out HCV and HBV testing in EDs in the UK. The model used data from UK studies of ED testing to parameterize the HCV and HBV prevalence (1.4% HCV RNA, 0.84% HBsAg), test costs, and intervention effects (contact rates and linkage to care). For HCV, we used an antibody test cost of £3.64 and RNA test cost of £68.38, and assumed direct-acting antiviral treatment costs of £10 000. For HBV, we used a combined HBsAg and confirmatory test cost of £5.79. We also modeled the minimum prevalence of HCV (RNA-positive) and HBV (HBsAg) required to make ED testing cost-effective at a £20 000 willingness to pay per quality-adjusted life-year threshold. RESULTS: In the base case, ED testing was highly cost-effective, with…
- 50top 5.8%
Cost-Effectiveness of Antiviral Treatments for Pandemics and Outbreaks of Respiratory Illnesses, Including COVID-19: A Systematic Review of Published Economic Evaluations
Dalia Dawoud, Khaled Y. Soliman
37 citationsOpen access (PUBLIC-DOMAIN)doi:10.1016/j.jval.2020.07.002OpenAlex
Show abstractHide abstract
OBJECTIVE: To review published economic evaluations of antiviral treatment for pandemics and outbreaks of respiratory illnesses. METHODS: We conducted a systematic review to identify economic evaluations of antiviral treatment for pandemics and outbreaks of respiratory illnesses, including coronavirus disease 2019 (COVID-19). We searched Medline (EBSCOhost), EMBASE (Ovid), EconLit (Ovid), National Health Service Economic Evaluation Database (Ovid), and Health Technology Assessment (Ovid). The search was last rerun on July 5, 2020. Citation tracking and reference checking were used. Only full economic evaluations published as peer-reviewed articles in the last 10 years were included. Studies were quality assessed using the National Institute for Health and Care Excellence economic evaluation checklist. RESULTS: Overall, 782 records were identified, of which 14 studies met the inclusion criteria. The studies were mostly conducted in high-income countries. All were model-based. Seven (50%) were cost-utility analyses, 4 (28.6%) were cost-effectiveness analyses, 2 (14.3%) were…
How to read this list
The cohort is every article, review and book chapter OpenAlex attributes to Value in Health with publication year 2020, excluding retracted works and paratext such as editorials and errata. The top 50 by citation count are listed; the percentile is the rank divided by the cohort size. 16 of the 50 entries have an abstract in OpenAlex. Counts were read on 29 October 2026 and will not be updated on this page, so a quoted rank stays verifiable. Full rules on the methodology page.
Other journals, same idea
Work with these 25 papers in Kahubi
- The papers land in your library with their DOIs
- Ask anything across all of them, with citations
- Draft a literature review from the same sources
Free plan, no card. Your files stay private unless you share them.
Reading several of these?
Kahubi reads papers with you, keeps every citation traceable and drafts with sources you can check. Free plan, no card.